All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Which patients with aggressive B-cell NHL do not qualify for CAR-T?
Bookmark this article
During the 4th European CAR T-cell Meeting the Lymphoma Hub was pleased to speak with, Anna Sureda, Catalan Institute of Oncology, Barcelona, Spain, ES. We asked, Which patients with aggressive B-cell NHL do not qualify for CAR-T? We also asked, Is CAR-T a new standard-of-care for aggressive B-Cell non-hodgkins lymphoma (NHL)
Which patients with aggressive B-cell NHL do not qualify for CAR-T?
Sureda begins by outlining the results of two clinical trials from ASH 2021 that compared SoC followed by allo-HSCT with anti-CD19 CAR T-cell therapy. Sureda expressed that those patients deemed ineligible for treatment with CAR T-cell therapy in these trials would generally not qualify for CAR-T. She goes on to outline a third, less defined group of patients which might not qualify that achieve a complete remission with second line chemotherapy.
Finally Sureda hypothesizes a change in the standard of care for patients with second line aggressive NHL.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox